Thymosin Alpha-1 in Cancer: From Lab Bench to Patient Bedside
Thymosin alpha-1 combined with low-dose interferon or IL-2 showed high efficacy in both experimental cancers and human clinical trials, positioning it as a promising cancer immunotherapy adjuvant.
Quick Facts
What This Study Found
Thymosin alpha-1 combined with low-dose IFN or IL-2 shows high efficacy against cancers in both preclinical models and human clinical trials, supporting its role as a cancer immunotherapy adjuvant.
Key Numbers
How They Did This
Review of basic research and clinical trial data on thymosin alpha-1 in cancer, covering combination with interferon, IL-2, and conventional cancer therapies.
Why This Research Matters
Modern cancer immunotherapy is transforming oncology. Thymosin alpha-1 as an affordable, well-tolerated immune enhancer could complement expensive checkpoint inhibitors and expand immunotherapy access.
The Bigger Picture
Cancer immunotherapy is increasingly combination-based. Thymosin alpha-1's ability to enhance immune responses with minimal toxicity makes it an ideal partner for other immunotherapies and conventional treatments.
What This Study Doesn't Tell Us
Brief review with limited detailed clinical data. The specific cancer types and trial designs were not comprehensively described. Larger trials needed for definitive evidence.
Questions This Raises
- ?How does thymosin alpha-1 compare to modern checkpoint inhibitors?
- ?Which cancers respond best to thymosin alpha-1 combination therapy?
- ?Can thymosin alpha-1 enhance checkpoint inhibitor responses?
Trust & Context
- Key Stat:
- Bench to bedside Thymosin alpha-1 has successfully transitioned from laboratory anti-tumor studies to human clinical trials showing cancer treatment benefit
- Evidence Grade:
- Moderate evidence from a translational review covering both preclinical and clinical data, though individual trial details are limited.
- Study Age:
- Published in 2000. Thymosin alpha-1 has continued to be used clinically as a cancer immunotherapy adjuvant in various countries.
- Original Title:
- Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.
- Published In:
- International journal of immunopharmacology, 22(12), 1067-76 (2000)
- Authors:
- Garaci, E(5), Pica, F(2), Rasi, G(3), Favalli, C
- Database ID:
- RPEP-00591
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is thymosin alpha-1 used for cancer today?
Yes, in some countries it's used as an immune-boosting adjunct to cancer treatment. It's combined with conventional therapies to enhance the immune system's ability to fight tumors.
How does it compare to newer immunotherapies?
Thymosin alpha-1 is a general immune enhancer, while newer drugs like checkpoint inhibitors target specific immune brakes. They may work well together, with thymosin alpha-1 boosting overall immunity while checkpoint inhibitors remove specific blocks.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00591APA
Garaci, E; Pica, F; Rasi, G; Favalli, C. (2000). Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.. International journal of immunopharmacology, 22(12), 1067-76.
MLA
Garaci, E, et al. "Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.." International journal of immunopharmacology, 2000.
RethinkPeptides
RethinkPeptides Research Database. "Thymosin alpha 1 in the treatment of cancer: from basic rese..." RPEP-00591. Retrieved from https://rethinkpeptides.com/research/garaci-2000-thymosin-alpha-1-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.